Background This asthma guideline update focuses on the management of individuals with
asthma at the mild end of the spectrum. It applies to children 1 year of age and over and …

OBJECTIVES: Children with status asthmaticus refractory to first-line therapies of systemic
corticosteroids and inhaled beta-agonists often receive additional treatments. Because there …

In early December 2008, the Food and Drug Administration (FDA) held an unusual joint
meeting of the Pulmonary–Allergy Drugs Advisory Committee, the Drug Safety and Risk …

In recent years, asthma research has focused intensely on the severe part of the disease
spectrum, leading to new treatments, mostly therapeutic monoclonal antibodies. However …

Appropriate use of biologics in severe asthma should be supported by further understanding
of biomarkers predicting response to targeted therapy. Because of their association with …

Background: Asthma is a major health problem and the most frequent cause of chronic
illness and emergency department (ED) visits in children. Limited data examining the ED …

Background The safety of long-acting β2 agonist (LABA) therapy in asthma remains
controversial but no large scale analyses have been published of LABA safety in children …

BACKGROUND: Regular use of inhaled anti-inflammatory (AI) medication improves
outcomes for children with persistent asthma. OBJECTIVE: To relate 3 measures of asthma …

Studies were assessed independently by two review authors for methodological quality and
data extraction. Confirmation was obtained from the trialists when possible. The primary …

To cite this article: Arellano FM, Arana A, Wentworth CE, Vidaurre CF, Chipps BE.
Prescription patterns for asthma medications in children and adolescents with health care …